AAAAAA

   
Results: 1-9 |
Results: 9
DESIGN AND SYNTHESIS OF N-ALKYLATED SACCHARINS AS SELECTIVE ALPHA-1A ADRENERGIC-RECEPTOR ANTAGONISTS
Authors: NERENBERG JB ERB JM THOMPSON WJ LEE HY GUARE JP MUNSON PM BERGMAN JM HUFF JR BROTEN TP CHANG RSL CHEN TB OMALLEY S SCHORN TW SCOTT AL
Citation: Jb. Nerenberg et al., DESIGN AND SYNTHESIS OF N-ALKYLATED SACCHARINS AS SELECTIVE ALPHA-1A ADRENERGIC-RECEPTOR ANTAGONISTS, Bioorganic & medicinal chemistry letters, 8(18), 1998, pp. 2467-2472
NO]CARBONYL]-PIPERAZINYL]-6,7-DIMETHOXYQUINAZOLINE (L-765,314) - A POTENT AND SELECTIVE ALPHA(1B) ADRENERGIC-RECEPTOR ANTAGONIST
Authors: PATANE MA SCOTT AL BROTEN TP CHANG RSL RANSOM RW DISALVO J FORRAY C BOCK MG
Citation: Ma. Patane et al., NO]CARBONYL]-PIPERAZINYL]-6,7-DIMETHOXYQUINAZOLINE (L-765,314) - A POTENT AND SELECTIVE ALPHA(1B) ADRENERGIC-RECEPTOR ANTAGONIST, Journal of medicinal chemistry, 41(8), 1998, pp. 1205-1208
IN-VIVO PHARMACOLOGY OF A NOVEL AT(1) SELECTIVE ANGIOTENSIN-II RECEPTOR ANTAGONIST, MK-996
Authors: KIVLIGHN SD ZINGARO GJ GABEL RA BROTEN TP SCHORN TW SCHAFFER LW NAYLOR EM CHAKRAVARTY PK PATCHETT AA GREENLEE WJ SIEGL PKS
Citation: Sd. Kivlighn et al., IN-VIVO PHARMACOLOGY OF A NOVEL AT(1) SELECTIVE ANGIOTENSIN-II RECEPTOR ANTAGONIST, MK-996, American journal of hypertension, 8(1), 1995, pp. 58-66
PREVENTION OF HYPERTENSION AND CARDIAC PATHOLOGY BY LOSARTAN DURING CHRONIC NITRIC-OXIDE INHIBITION
Authors: BROTEN TP SCOTT AL CARTWRIGHT M SIEGL PKS
Citation: Tp. Broten et al., PREVENTION OF HYPERTENSION AND CARDIAC PATHOLOGY BY LOSARTAN DURING CHRONIC NITRIC-OXIDE INHIBITION, The FASEB journal, 9(3), 1995, pp. 329-329
PHARMACOLOGY OF LOSARTAN, AN ANGIOTENSIN-II RECEPTOR ANTAGONIST, IN ANIMAL-MODELS OF HYPERTENSION
Authors: SIEGL PKS KIVLIGHN SD BROTEN TP
Citation: Pks. Siegl et al., PHARMACOLOGY OF LOSARTAN, AN ANGIOTENSIN-II RECEPTOR ANTAGONIST, IN ANIMAL-MODELS OF HYPERTENSION, Journal of hypertension, 13, 1995, pp. 15-21
IN-VIVO PHARMACOLOGY OF AN ANGIOTENSIN AT(1) RECEPTOR ANTAGONIST WITHBALANCED AFFINITY FOR ANGIOTENSIN AT(2) RECEPTORS
Authors: KIVLIGHN SD ZINGARO GJ GABEL RA BROTEN TP CHANG RSL ONDEYKA DL MANTLO NB GIBSON RE GREENLEE WJ SIEGL PKS
Citation: Sd. Kivlighn et al., IN-VIVO PHARMACOLOGY OF AN ANGIOTENSIN AT(1) RECEPTOR ANTAGONIST WITHBALANCED AFFINITY FOR ANGIOTENSIN AT(2) RECEPTORS, European journal of pharmacology, 294(2-3), 1995, pp. 439-450
IN-VIVO PHARMACOLOGY AND ANTIHYPERTENSIVE ACTIVITY OF L-159,282 (MK-996) A NONPEPTIDE ANGIOTENSIN-II (A-II) RECEPTOR ANTAGONIST
Authors: SIEGL PKS GABEL RA ZINGARO GJ SCHORN T HARVEY C ARBEGAST P BROTEN TP SCHAFFER LW CHAKRAVARTY PK GREENLEE W NAVLOR E PATCHETT AA KIVLIGHN SD
Citation: Pks. Siegl et al., IN-VIVO PHARMACOLOGY AND ANTIHYPERTENSIVE ACTIVITY OF L-159,282 (MK-996) A NONPEPTIDE ANGIOTENSIN-II (A-II) RECEPTOR ANTAGONIST, The FASEB journal, 8(5), 1994, pp. 10000881-10000881
LOSARTAN AND ENALAPRIL PREVENT CARDIAC-HYPERTROPHY AND INTRAMURAL CORONARY ARTERIAL HYPERTROPHY AND FIBROSIS IN A LOW RENIN MODEL OF HYPERTENSION
Authors: BROTEN TP GIBSON RE CARTWRIGHT ME BURKHOLDER DB FIORAVANTI C SCOTT AL SIEGL PKS
Citation: Tp. Broten et al., LOSARTAN AND ENALAPRIL PREVENT CARDIAC-HYPERTROPHY AND INTRAMURAL CORONARY ARTERIAL HYPERTROPHY AND FIBROSIS IN A LOW RENIN MODEL OF HYPERTENSION, The FASEB journal, 8(4), 1994, pp. 10000310-10000310
A HIGHLY POTENT, ORALLY-ACTIVE IMIDAZO[4,5-B]PYRIDINE BIPHENYLACYLSULFONAMIDE (MK-996-L-159,282) - A NEW ANGIOTENSIN-II RECEPTOR ANTAGONIST
Authors: CHAKRAVARTY PK NAYLOR EM CHEN A CHANG RSL CHEN TB FAUST KA LOTTI VJ KIVLIGHN SD GABLE RA ZINGARO GJ SCHORN TW SCHAFFER LW BROTEN TP SIEGL PKS PATCHETT AA GREENLEE WJ
Citation: Pk. Chakravarty et al., A HIGHLY POTENT, ORALLY-ACTIVE IMIDAZO[4,5-B]PYRIDINE BIPHENYLACYLSULFONAMIDE (MK-996-L-159,282) - A NEW ANGIOTENSIN-II RECEPTOR ANTAGONIST, Journal of medicinal chemistry, 37(24), 1994, pp. 4068-4072
Risultati: 1-9 |